Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group
-
Published:2016-12-13
Issue:1
Volume:18
Page:127-135
-
ISSN:1470-269X
-
Container-title:The Pharmacogenomics Journal
-
language:en
-
Short-container-title:Pharmacogenomics J
Author:
Floyd J S, Sitlani C M, Avery C L, Noordam R, Li XORCID, Smith A V, Gogarten S M, Li J, Broer L, Evans D S, Trompet S, Brody J A, Stewart J D, Eicher J D, Seyerle A A, Roach J, Lange L A, Lin H J, Kors J A, Harris T B, Li-Gao R, Sattar N, Cummings S R, Wiggins K L, Napier M D, Stürmer T, Bis J C, Kerr K F, Uitterlinden A G, Taylor K D, Stott D J, de Mutsert R, Launer L J, Busch E L, Méndez-Giráldez R, Sotoodehnia N, Soliman E Z, Li Y, Duan Q, Rosendaal F R, Slagboom P E, Wilhelmsen K C, Reiner A P, Chen Y-DI, Heckbert S R, Kaplan R C, Rice K M, Jukema J W, Johnson A D, Liu Y, Mook-Kanamori D O, Gudnason V, Wilson J G, Rotter J I, Laurie C C, Psaty B M, Whitsel E A, Cupples L A, Stricker B H
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference84 articles.
1. Nathan DM . Diabetes: advances in diagnosis and treatment. JAMA 2015; 314: 1052–1062. 2. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK . Use of antidiabetic drugs in the u.s., 2003-2012. Diabetes Care 2014; 37: 1367–1374. 3. Meinert CL, Knatterud GL, Prout TE, Klimt CR . A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (Suppl): 789–830. 4. Monami M, Genovese S, Mannucci E . Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 938–953. 5. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR . Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 43–51.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|